Conjugated androgen metabolites: a novel biomarker for androgen exposure in hirsutism?

Conditions: Endocriene aandoeningen van de bijnier/gonadale functie/perifere weefsels
Excessive hair growth in women
hirsutism

Registration Number: NL-OMON56909

Lead Sponsor: Amsterdam UMC

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Not specified

Target Recruitment: 80

Inclusion Criteria

Premenopausal women (18-40 years) with hirsutism:
- Ability to provide informed consent;
- Ability to speak and understand Dutch;
- The presence of hirsutism.

Healthy premenopausal women (18-40 years):
- Ability to provide informed consent;
- Ability to speak and understand Dutch;
- Consider themselves healthy; no signs of hirsutism, hyperandrogenism or other
endocrine pathologies.

Exclusion Criteria

Premenopausal women (18-40 years) with and without hirsutism:
- Primary ovarian insufficiency (POI) or premature ovarian failure (POF);
- Pregnancy;
- Any of the following medications:
o Oral contraceptives
o Anocrine/danazol;
o Minoxidil;
o Fluoxetine;
o Celestone;
o Dexamethasone;
o Hydrocortisone;
o (Methyl)prednisolone;
o Prednisone;
o Spironolactone;
o Flutamide;
o Finasteride;
o Cimetidine;
o Anabolic steroids.

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- Conjugated androgen metabolites: 3a-diol-3G, 3a-diol-17G, ADT-G<br /><br>- 3G/17G-ratio</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Results of the psychological questionnaire<br /><br>- HOMA-index (serum measurement)<br /><br>- HbA1c, fasting insulin and glucose<br /><br>- Lipid profile (serum total cholesterol, LDL, VLDL, HDL, triglycerides)<br /><br>- Liver enzymes (serum ALP, ALT, AST, GGT, ELF)</p><br>